Julie Papanek Grant - Dec 8, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role: Director
Signature: /s/ Charles N. York II, Attorney-in-Fact
Stock symbol: DAWN
Transactions as of: Dec 8, 2022
Transactions value $: -$96,210
Form type: 4
Date filed: 12/12/2022, 03:56 PM
Previous filing: Dec 5, 2022
Next filing: Jan 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DAWN	Common Stock	Sale	-$96.2K	-4.36K	-1.06%	$22.08	405K	Dec 8, 2022	See Footnote	F1, F2, F3
holding	DAWN	Common Stock						2.36K	Dec 8, 2022	See Footnote	F4
holding	DAWN	Common Stock						2.55M	Dec 8, 2022	See Footnote	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.62 to $22.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
F4	Represents shares held by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 of which the Reporting Person and her spouse are co-trustees. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
F5	Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.